2006

1. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae

   Journal of Antimicrobial Chemotherapy, Vol. 57, Núm. 3, pp. 536-545